Bristol Myers Squibb, Exelixis Granted FDA Priority Review For Kidney Cancer TreatmentInvestors Business Daily • 10/19/20
U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell CarcinomaBusiness Wire • 10/19/20
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell CarcinomaBusiness Wire • 10/16/20
Bristol Myers Squibb Presents Positive Late-Breaking Data from Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Adult Patients with Moderate to Severe Ulcerative ColitisBusiness Wire • 10/10/20
MYOKARDIA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of MyoKardia, Inc. - MYOKBusiness Wire • 10/09/20
Bristol Myers Shares Up On Positive Data For Lung Cancer TreatmentInvestors Business Daily • 10/07/20
Opdivo (nivolumab) Plus Chemotherapy Shows Statistically Significant Improvement in Pathologic Complete Response as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 TrialBusiness Wire • 10/07/20
Myokardia Analysts See Mavacamten As Blockbuster Opportunity For Bristol-Myers SquibbBenzinga • 10/06/20
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of MyoKardia, Inc. to Bristol Myers SquibbNewsfile Corp • 10/05/20